Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

It blocks and destroys bile ducts in the liver. Doctors used to call it “primary biliary cirrhosis.” “Biliary” means bile. That’s a digestive fluid that helps your body get rid of ...

Primary biliary cirrhosis (PBC) is a chronic, cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, resulting in chronic cholestasis, portal inflammation ...

The association between celiac disease and primary biliary cirrhosis is well established. The breakdown of gut–liver axis equilibrium plays a central role in the development of immune disorders ...

A low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, polyols) diet can improve patients' irritable ...

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis ... leading to cirrhosis. It affects around 130,000 people in the US ...

Cirrhosis progresses in stages, from a compensated phase with few symptoms to a decompensated phase with serious complications like ascites and hepatic encephalopathy. Early diagnosis is crucial and ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the ... so most patients already ...

HCC occurred in 1.27% of patients with PBC, which is lower than the recommended threshold for cost-effective surveillance.

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Symptoms vary, but can include itching, fatigue, abdominal pain and jaundice, with patients also experiencing serious complications such as liver cirrhosis and an increased ... the brand name Iqirvo ...